|
|
 |
 |
 |
Dosage form Development
|
 |
Our formulation laboratories are fully equipped to work on new chemical entities (NCE’s), generics, specialty products, reformulation and life cycle extension of existing molecules. We have the expertise for developing robust formulations for molecules that have solubility, bioavailability and stability concerns. We utilize process analytical technologies (PAT) in developing quality and cost effective products within the committed timelines.
We have a fully compliant cGMP facility for scale-up and manufacture of clinical supplies.
|
|
|
 |
Preformulation Development |
 |
Formulation Development |
 |
Analytical R&D |
| |
|
| Preformulation Development |
|
|
|
| Formulation Development |
|
Capabilities:
Solids: Tablets, capsules, granules and powders
Liquids: Oral solutions, syrups and suspensions
Semi-solids: Creams and ointments
Parenterals: Small volume, sterile powders
Technologies:
- Immediate release
- Sustained release (matrix and multiparticulate)
- Delayed release
- Hot melt filling of capsules.
- Aqueous and organic film coating.
- Active coating of tablets, granules, beads and soft and hard gelatin capsules
- Lyophilized powders
Potent Molecules:
Aizant has established the environmental, health and safety systems in its facility to develop highly potent compounds.
Aizant has implemented the following controls to handle potent compounds.
- Engineering
- Personal safety
- Administrative
|
|
|
| Analytical R&D |
Analytical research and development (AR&D) works closely with chemical process, product development and quality assurance teams. AR&D ensures the stability and quality of clinical supplies and to provide the necessary documents for global regulatory submissions. AR&D operates in a cGLP and cGMP compliant environment to develop validated methods for the physical, chemical and microbiological characterization of the drug substance, the drug product, excipients and packaging components. AR&D also provides support for the testing and release of pre-clinical and clinical supplies. AR&D is also responsible for analyzing the stability samples of development and marketed drug products. |
Drug substance characterization
- Identification, potency, moisture, residual solvents and chromatographic purity and degradation products
- Solid state characterization (amorphous, crystalline, hydrate, etc)
- Comparability studies to bridge synthesis changes
- Reference Standards
Formulation characterization
- Identification, assay, moisture content, related substances, chiral purity, dissolution
- Dose/content uniformity, blend uniformity, stratified sampling and other in-process methods
- Preservatives, antioxidants and other minor components
- Polymorphic purity
- Forced degradation studies
|
|
|
|
 |
|
|